← Back to Clinical Trials
Recruiting NCT07607262

NCT07607262 RIPB Versus EOIPB for Pain Control After Laparoscopic Cholecystectomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07607262
Status Recruiting
Phase
Sponsor Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital
Condition Laparoscopic Cholecystectomy
Study Type OBSERVATIONAL
Enrollment 60 participants
Start Date 2026-05-15
Primary Completion 2026-06-09

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type OBSERVATIONAL
Interventions
Bilateral Ultrasound-Guided Recto-Intercostal Plane BlockBilateral Ultrasound-Guided External Oblique Intercostal Plane Block

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 60 participants in total. It began in 2026-05-15 with a primary completion date of 2026-06-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This prospective observational study aims to compare the effects of bilateral ultrasound-guided recto-intercostal plane block(RIPB) and bilateral ultrasound-guided external oblique intercostal plane block(EOIPB) on postoperative analgesia in patients undergoing elective laparoscopic cholecystectomy under general anesthesia. Both blocks are performed after anesthesia induction as part of routine preemptive multimodal analgesia practice. Patients who receive bilateral recto-intercostal plane block will be included in the RIPB group, and patients who receive bilateral external oblique intercostal plane block will be included in the EOIPB group. The primary outcome is cumulative intravenous tramadol consumption via patient-controlled analgesia during the first 24 postoperative hours. Secondary outcomes include postoperative pain scores at rest and during activity, rescue analgesic requirement, postoperative nausea and vomiting, time to mobilization, length of hospital stay, quality of recovery assessed using the Quality of Recovery-15 questionnaire, and block-related complications.

Eligibility Criteria

Inclusion Criteria: * Age between 18 and 75 years * American Society of Anesthesiologists (ASA) physical status I-III * Scheduled for elective laparoscopic cholecystectomy under general anesthesia * Written informed consent obtained Exclusion Criteria: * Refusal to participate * Inability to understand the study protocol or provide informed consent * Known allergy to local anesthetics, tramadol, paracetamol, dexketoprofen, or other study drugs * Chronic opioid or steroid use * Psychiatric or cognitive disorder preventing reliable pain assessment * Inability to use patient-controlled analgesia * Pregnancy or breastfeeding * Coagulopathy * Infection at the block site * Difficult or prolonged intubation requiring three or more attempts * Conversion to open surgery * Surgery lasting longer than 120 minutes * Intraoperative or postoperative complications requiring deviation from the standard analgesia protocol

Contact & Investigator

Central Contact

Berfin G Özelsel, MD

✉ berfinozelsel@gmail.com

📞 +90 216 606 33 00

Frequently Asked Questions

Who can join the NCT07607262 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Laparoscopic Cholecystectomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07607262 currently recruiting?

Yes, NCT07607262 is actively recruiting participants. Contact the research team at berfinozelsel@gmail.com for enrollment information.

Where is the NCT07607262 trial being conducted?

This trial is being conducted at Sancaktepe, Turkey (Türkiye).

Who is sponsoring the NCT07607262 clinical trial?

NCT07607262 is sponsored by Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology